{"entity":{"id":"nct07390383","kind":"trial","name":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","aka":[],"tldr":"A phase 2 trial of Capecitabine, Tislelizumab and Oxaliplatin in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.","summary":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] is a phase 2 interventional study registered as NCT07390383 by Nanjing Leads Biolabs Co.,Ltd, with 110 participants planned, started 2026-04-13 and due to reach its primary completion in 2028-05-30. Interventions recorded: LBL-024 for Injection, Capecitabine tablets, Tislelizumab Injection and Oxaliplatin injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07390383","url":"https://clinicaltrials.gov/study/NCT07390383"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["capecitabine","tislelizumab","oxaliplatin"],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07390383","phase":"2","setting":"An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 04]","sponsor":"Nanjing Leads Biolabs Co.,Ltd","participation":[{"nct":"NCT07390383","source":"https://clinicaltrials.gov/study/NCT07390383","fetchedAt":"2026-10-07T16:55:43.582Z","studySha256":"171e1b9cb7cef9c5ef2b8da9683628bab26d3cfe59306ddd0a6c2beb163f396c","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-13","leadSponsor":"Nanjing Leads Biolabs Co.,Ltd","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":110,"enrolmentType":"ESTIMATED","siteCount":7,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-04-13","startedType":"actual","enrolled":110,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07390383/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}]}}